Agenus Announced Data from Phase 2 Trials of Balstilimab
Agenus (AGEN) immuno-oncology company announced that data from two Phase 2 trials of balstilimab alone and in combination with zalifrelimab will be orally presented in at the upcoming European Society of Medical Oncology (ESMO) Conference on September 18, 2020.
The data will be presented by Dr. David O'Malley, Professor . . .